MRC1 and neoplasm: To monitor the dynamics of MMR+ TAMs in tumors, an anti-MMR nanobody, cross-reactive with mouse and human CD206, was developed and radiolabeled with 18F and then injected into 3LL-R tumor-bearing mice [123].